Art. -Nr.: HY-15512

Copy Link Print Information

OTSSP167

(Synonyms: OTS167)

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

OTSSP167 (OTS167) is a highly potent and ATP-competitive MELK inhibitor with IC₅₀ value of 0.41 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.27%
CAS. Nr.: 1431697-89-0
Formel: C₂₅H₂₈Cl₂N₄O₂
Molecular Weight:487.42

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

OTSSP167 Chemical Structure

CAS. Nr.: 1431697-89-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

OTSSP167 (OTS167) is a highly potent and ATP-competitive MELK inhibitor with IC₅₀ value of 0.41 nM.

IC₅₀ & Target

IC50: 0.41 nM (MELK)

Cellular Effect

Cell Line	Type	Value	Description	References
769-P	IC₅₀	20.1 nM Compound: OTS167	Cytotoxicity against human 769-P cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human 769-P cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
786-0	IC₅₀	23.9 nM Compound: OTS167	Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human 786-O cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
A549	IC₅₀	6.7 nM Compound: OTS167	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 30108692]
BGC-823	IC₅₀	25 nM Compound: OTS167	Antiproliferative activity against human BGC823 cells after 24 to 96 hrs by CCK8 assay Antiproliferative activity against human BGC823 cells after 24 to 96 hrs by CCK8 assay	[PMID: 30108692]
CAKI-1	IC₅₀	12.4 nM Compound: OTS167	Cytotoxicity against human Caki1 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human Caki1 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
CAKI-2	IC₅₀	38.7 nM Compound: OTS167	Cytotoxicity against human Caki2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human Caki2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
CWR22R	IC₅₀	6 nM Compound: OTS167	Antiproliferative activity against human 22Rv1 cells Antiproliferative activity against human 22Rv1 cells	[PMID: 30108692]
DMS-114	IC₅₀	2.1 nM Compound: OTS167	Cytotoxicity against human DMS114 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human DMS114 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
DMS-273	IC₅₀	8.4 nM Compound: OTS167	Cytotoxicity against human DMS273 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human DMS273 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
DU-4475	IC₅₀	2.3 nM Compound: OTS167	Antiproliferative activity against human DU4475 cells Antiproliferative activity against human DU4475 cells	[PMID: 30108692]
HEK-293T	CC₅₀	64 nM Compound: 5; OTS167	Cytotoxicity against human HEK293T cells transfected with DYRK1A co-tranfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as reduction in luciferase activity by measuring cell number Cytotoxicity against human HEK293T cells transfected with DYRK1A co-tranfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as reduction in luciferase activity by measuring cell number	[PMID: 31757680]
HEK-293T	EC₅₀	5 nM Compound: 5; OTS167	Inhibition of human DYRK1A transfected in HEK293T cells co-transfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as derepression of NFAT-dependent luciferase activity measured after 48 hrs by luciferase assay Inhibition of human DYRK1A transfected in HEK293T cells co-transfected with Renilla plasmid, pGL3-NFAT and NFATc1 assessed as derepression of NFAT-dependent luciferase activity measured after 48 hrs by luciferase assay	[PMID: 31757680]
K562	IC₅₀	33 nM Compound: OTS167	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
KG-1	IC₅₀	16.9 nM Compound: OTS167	Cytotoxicity against human KG1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human KG1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
KG-1a	IC₅₀	26.4 nM Compound: OTS167	Cytotoxicity against human KG1a cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human KG1a cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
ML-2	IC₅₀	33.8 nM Compound: OTS167	Cytotoxicity against human ML2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human ML2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
MOLM-13	IC₅₀	17.5 nM Compound: OTS167	Cytotoxicity against human MOLM13 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MOLM13 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
MV4-11	IC₅₀	7.9 nM Compound: OTS167	Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MV4-11 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
NCI-H146	IC₅₀	7.9 nM Compound: OTS167	Cytotoxicity against human NCI-H146 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H146 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
NCI-H2171	IC₅₀	4.7 nM Compound: OTS167	Cytotoxicity against human NCI-H2171 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H2171 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
NCI-H446	IC₅₀	6.2 nM Compound: OTS167	Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H446 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
NCI-H524	IC₅₀	1.9 nM Compound: OTS167	Cytotoxicity against human NCI-H524 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H524 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
NCI-H69	IC₅₀	0.8 nM Compound: OTS167	Cytotoxicity against human H69 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human H69 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
NCI-H82	IC₅₀	1.7 nM Compound: OTS167	Cytotoxicity against human H82 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human H82 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
SBC-3	IC₅₀	4.3 nM Compound: OTS167	Cytotoxicity against human SBC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human SBC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
SBC-5	IC₅₀	2.8 nM Compound: OTS167	Cytotoxicity against human SBC5 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human SBC5 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108692]
SGC-7901	IC₅₀	25 nM Compound: OTS167	Antiproliferative activity against human SGC7901 cells after 24 to 96 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 24 to 96 hrs by CCK8 assay	[PMID: 30108692]
T47D	IC₅₀	4.3 nM Compound: OTS167	Antiproliferative activity against human T47D cells Antiproliferative activity against human T47D cells	[PMID: 30108692]
THP-1	IC₅₀	15.6 nM Compound: OTS167	Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]
U-937	IC₅₀	69.8 nM Compound: OTS167	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30108692]

In Vitro

OTSSP167 inhibits the growth of A549 (lung), T47D (breast), DU4475 (breast), 22Rv1 (prostate) and HT1197 (bladder) cancer cells with IC₅₀ values of 6.7, 4.3, 2.3, 6.0 and 97 nM, respectively^[1]. OTSSP167 can abrogate the mitotic checkpoint, disrupt MCC and MCC-APC/C interaction in MCF7 cells. OTSSP167 causes GFP-MELK localization to cell cortex in prometaphase cells^[2]. OTSSP167 is a MELK selective inhibitor, exhibits a strong in vitro activity, conferring an IC₅₀ of 0.41 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

OTSSP167 (20 mg/kg, i.v.) results in tumor growth inhibition (TGI) of 73% in xenograft mouse model; OTSSP167 (1, 5, and 10 mg/kg, p.o.) reveals TGI of 51, 91, and 108%, respectively. OTSSP167 (20 mg/kg, p.o.) shows no tumor growth suppressive effect on PC-14 xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1431697-89-0
Appearance Solid
Molecular Weight 487.42
Formel C₂₅H₂₈Cl₂N₄O₂
Color Light yellow to yellow
SMILES

ClC1=CC(C2=CC=C(N=CC(C(C)=O)=C3N[C@H]4CC[C@H](CN(C)C)CC4)C3=N2)=CC(Cl)=C1O
Synonyms

OTS167
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (23)

All IPWB

Sort by:

Journal Impact Factor

Mol Cancer

Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. [Abstract]

2014 May 4;13:100. PMID: 24885567

OTSSP167 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2014 May 4;13:100. [Abstract]

MELK specific inhibitor OTSSP167 suppresses cell migration and invasion. A, Immunoblotting representing MELK expression in SGC7901 cell following OTSSP167 treatment for indicated period. In the upper panel, SGC7901 cell are treated with different concentration (0, 0.1, 1 μM) of OTSSP167 for 1 h and 2 h. In the lower panel, SGC7901/vector and SGC7901/MELK cell are treated with 1 μM OTSSP167 for 2 h. C, SGC7901/vector and SGC7901/MELK cells are treated with 1 μM OTSSP167 for indicated period and
Nat Cancer

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance. [Abstract]

2024 Aug;5(8):1250-1266. PMID: 38992135
Neuro Oncol

MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. [Abstract]

2020 Jan 11;22(1):58-69. PMID: 31504799
Blood Cancer J

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. [Abstract]

2019 Nov 18;9(12):87. PMID: 31740676

OTSSP167 purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Nov 18;9(12):87. [Abstract]

Expression of MELK and Aurora B kinase (AurB) is determined in samples from vehicle and OTSSP167-treated mice. β-actin is used as loading control.
Clin Cancer Res

MELK Inhibition in Diffuse Intrinsic Pontine Glioma. [Abstract]

2018 Nov 15;24(22):5645-5657. PMID: 30061363

OTSSP167 purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Nov 15;24(22):5645-5657. [Abstract]

Western blot showing protein levels of MELK, PPARγ and phospho-PPARγ^S112 in JHH-DIPG-01, HSJD-DIPG-12, SF7761 and HSJD-DIPG-07 cells after 48 hours treatment with either 20 nM or 50 nM OTSSP167.
EMBO Mol Med

Identification of potential therapeutic targets in prostate cancer through a cross-species approach. [Abstract]

2018 Mar;10(3). pii: e8274. PMID: 29437778

OTSSP167 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2018 Mar;10(3). pii: e8274. [Abstract]

Validation of effects of OTS167 on phosphorylation of p90RSK and its targets. C4-2b cells are treated with vehicle or 30 nM OTS167 for the indicated times, and levels of total and phosphorylated proteins are determined by Western blot analysis. β-Actin is used as a loading control.
Free Radic Biol Med

Pharmacological inhibition of MELK restricts ferroptosis and the inflammatory response in colitis and colitis-propelled carcinogenesis. [Abstract]

2021 Aug 20:172:312-329. PMID: 34144192
Elife

MELK expression correlates with tumor mitotic activity but is not required for cancer growth. [Abstract]

2018 Feb 8;7:e32838. PMID: 29417930
Elife

CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. [Abstract]

2017 Mar 24;6:e24179. PMID: 28337968
Int J Mol Sci

MELK as a Mediator of Stemness and Metastasis in Aggressive Subtypes of Breast Cancer. [Abstract]

2025 Mar 3;26(5):2245. PMID: 40076867
Int J Oncol

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines. [Abstract]

2022 Jul;61(1):89. PMID: 35642662
Eur J Pharmacol

OTSSP167 suppresses TNBC brain metastasis via ROS-driven P38/JNK and FAK/ERK pathways. [Abstract]

2025 Oct 5:1004:178017. PMID: 40744390
FEBS J

Nemo-like kinase modulates glucocorticoid-induced erythroid progenitor differentiation by regulating stability of the glucocorticoid receptor. [Abstract]

2026 Feb 2. PMID: 41629744
Gynecol Oncol

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. [Abstract]

2017 Apr;145(1):159-166. PMID: 28214016

OTSSP167 purchased from MedChemExpress. Usage Cited in: Gynecol Oncol. 2017 Apr;145(1):159-166. [Abstract]

Western blotting demonstrates that 100 nM OTSSP167 for 48 h produces marked PARP-1 cleavage in HGSOC cell lines whereas no or weak PARP-1 cleavage is observed in normal ovarian surface epithelial cells (HOSE6-3) and in the fallopian tubal cells (FT33-tag, FT190, FT237).
Sci Rep

Zinc finger protein ZPR9 functions as an activator of AMPK-related serine/threonine kinase MPK38/MELK involved in ASK1/TGF-β/p53 signaling pathways. [Abstract]

2017 Feb 14;7:42502. PMID: 28195154

OTSSP167 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Feb 14;7:42502. [Abstract]

In vitro kinase assays are performed using MPK38 immunoprecipitates, which are obtained from cell lysates of wild-type and clonal CRISPR/Cas9 ZPR9 (T252A) KI isolates, treated with (+) or without (−) OTSSP167 (1 μM, 2 h), a MPK38-specific inhibitor, in the presence of ZPR9 immunoprecipitates as the substrate. Recombinant MPK38 proteins (lower panels), which were expressed in bacterial cells, treated with (+) or without (−) OTSSP167 are also used instead of the MPK38 immunoprecipitates (upper pan
Adv Ther (Weinh)

2025 Oct 24.
PLoS One

Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. [Abstract]

2017 Feb 24;12(2):e0172832. PMID: 28235006

OTSSP167 purchased from MedChemExpress. Usage Cited in: PLoS One. 2017 Feb 24;12(2):e0172832. [Abstract]

OTS167 reduces proliferation and regulates MELK transcript but not protein levels in TNBC cells. The MELK 52 kDa variant is highly expressed in the TNBC cell lines but not in luminal A MCF-7.
Biochem Biophys Res Commun

The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. [Abstract]

2014 Apr 25;447(1):7-11. PMID: 24657156
bioRxiv

2026 Apr 24.
University of Washington

2025.
Oncotarget

MELK is a novel therapeutic target in high-risk neuroblastoma. [Abstract]

2017 Dec 20;9(2):2591-2602. PMID: 29416794

OTSSP167 purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Dec 20;9(2):2591-2602. [Abstract]

Effects of OTSSP167 on PARP and Caspase-3 cleavages in NB cells are shown by immunoblotting assay.
Patent

US20160291017A1.

OTSSP167 purchased from MedChemExpress. Usage Cited in: Patent. US20160291017A1.

Mitotic MDA-MB-468 cells are treated for 30 min with vehicle or 200 nM OTSSP167, a MELK inhibitor. Lysates are used for immunoblotting.
Oncotarget

Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer. [Abstract]

2016 Feb 2;7(5):6266-80. PMID: 26701722

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 2.5 mg/mL (5.13 mM; ultrasonic and warming and adjust pH to 4 with 1M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0516 mL

10.2581 mL

20.5162 mL

5 mM

0.4103 mL

2.0516 mL

4.1032 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2.5 mg/mL (5.13 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

For in vitro kinase assay, MELK recombinant protein (0.4 μg) is mixed with 5 μg of each substrate in 20 μL of kinase buffer containing 30 mM Tris-HCl (pH), 10 mM DTT, 40 mM NaF, 10 mM MgCl₂, 0.1 mM EGTA with 50 μM cold-ATP and 10 Ci of [γ-³²P]ATP for 30 min at 30°C. The reaction Is terminated by addition of SDS sample buffer and boiled for 5 min prior to SDS-PAGE. The gel is dried and autoradiographed with intensifying screens at room temperature. OTSSP167 (final concentration of 10 nM) is dissolved in DMSO and added to kinase buffer before the incubation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

In vitro cell viability is measured by the colorimetric assay using Cell Counting Kit-8. Cells are plated in 100 μL in 96-well plates at a density that generates continual linear growth (A549, 1×10³ cells; T47D, 3×10³ cells; DU4475, 4×10³ cells; 22Rv1, 6×10³ cells; and HT1197, 2×10³ cells, in 100 μL per well). The cells are allowed to adhere overnight before exposure to OTSSP167 for 72 hours at 37°C. Plates are read using a spectrophotometer at a wavelength of 450 nm. All assays are carried out in triplicate.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

MDA-MB-231 cells are injected into the mammary fat pads of NOD.CB17-Prkdc^scid/J mice. A549, MIAPaCa-2 and PC-14 cells (1×10⁵ cells) are injected subcutaneously in the left flank of female BALB/cSLC-nu/nu mice. DU145 cells are injected subcutaneously in the left flank of male BALB/cSLC-nu/nu mice. When MDA-MB-231, A549, DU145, MIAPaCa-2, and PC-14 xenografts has reached an average volume of 100, 210, 110, 250, and 250 mm³, respectively, animals are randomized into groups of 6 mice (except for PC-14, for which groups of 3 mice are used). For oral administration, OTSSP167 and other compounds are prepared in a vehicle of 0.5% methylcellulose and given by oral garbage at the indicated dose and schedule. For intravenous administration, compounds are formulated in 5% glucose and injected into the tail vein. An administration volume of 10 mL per kg of body weight is used for both administration routes. Tumor volumes are determined every other day using a caliper.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chung S, Suzuki H, Miyamoto T, et al. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec 21. [Content Brief]

[2]. Li S, et al. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer. Oncotarget. 2016 Feb 2;7(5):6266-80. [Content Brief]

[3]. Ji W, et al. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Apr 15;11(4):e0153518. [Content Brief]

[4]. Cho YS, et al. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor. Biochem Biophys Res Commun. 2014 Apr 25;447(1):7-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0516 mL	10.2581 mL	20.5162 mL	51.2905 mL
DMSO	5 mM	0.4103 mL	2.0516 mL	4.1032 mL	10.2581 mL

Keywords

OTSSP167

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

OTSSP167

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) OTSSP167

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

OTSSP167

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Publications Citing Use of MedChemExpress (MCE) OTSSP167

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

OTSSP167 Related Classifications

HY-15512 Related Classifications